All I know re: swine flu is from the 7/2 PR:
NuGenerex Immuno-Oncology Announces
Plans to Address the New Emerging Pandemic Threat from
G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine
− NGIO has previously developed Ii-Key-H1 peptides for vaccines against epitopes to
2009 Swine Flu and 2004 Bird Flu with positive Phase I clinical safety and
immunologic data for Ii-Key-H1 peptide vaccine
− Ii-Key-H1 peptide sequence is 100% homologous in previous pandemic influenza
threats
− Potential to launch Ii-Key-H1 peptide vaccine for emerging pandemic threat from G4
EA H1N1 swine flu
− Published reference: Honglei et al. Prevalent Eurasian Avian-like H1N1 Swine
Influenza Virus with 2009 Pandemic Viral Genes Facilitating Human Infection.
Proceedings of the National Academy of Sciences; June 2020. (See Link)
https://www.pnas.org/content/early/2020/06/23...ticleShare
MIRAMAR, FL, July 2, 2020 – NuGenerex Immuno-Oncology today announced that the company
is launching a vaccine development effort to address the new, emerging pandemic threat from
a newly identified swine influenza virus. On June 29, 2020 scientists in China published a paper
in the Proceedings of the National Academy of Sciences identifying a new virus in pigs that has
the capacity to infect humans. This emerging virus is similar to the 2009 swine flu virus that is
estimated to have killed nearly 500,000 globally. Between April 12, 2009, and April 10, 2010,
the CDC estimates that the 2009 swine flu virus caused 60.8 million illnesses, 273,304
hospitalizations and 12,469 deaths in the United States. Of particular concern is that an
infection surveillance program with swine workers showed an elevated level of antibodies to
the G4 EA H1 influenza virus, indicating swine to human transmission and the potential for
another viral pandemic. NGIO is uniquely positioned to respond this pandemic threat as the
company has successfully completed a Phase I human clinical trial with an Ii-Key peptide
vaccine designed to elicit an immune response against the H1 hemagglutinin protein of the
2009 H1 swine influenza strain.
Joseph Moscato, CEO of NGIO stated, “Our Ii-Key immune activation technology is designed to
create targeted, highly specific vaccines that activate both the T-Cell and antibody responses
that make a “Complete Vaccine” against cancer antigens and viruses. The Ii-Key technology
platform was established to respond quickly, economically, and effectively to create vaccines
against viral and cancer antigens based upon the amino acid peptide sequences of the target
proteins that can be neutralized by an immune response. Importantly, Ii-Key peptide vaccines
have demonstrated safety, without signs of off-target immune responses or cytokine storm
effects in any of the Phase I and Phase II trials conducted to date. As such, the Ii-Key platform is
perfectly suited for inclusion in a pandemic preparedness portfolio, and we plan to pursue this
avenue to augment our clinical development program for Ii-Key immunotherapeutic cancer
vaccines as we progress toward a public listing for NuGenerex Immuno-Oncology on a national
exchange.”
Mr. Moscato continued, “With the explosion of the SARS-CoV-2 pandemic, we restarted the
pandemic vaccine development program conducted by NGIO from 2004 to 2010 and submitted
proposals to government agencies and international organizations to fund the development of
a COVID-19 vaccine. As we await the funding decisions, we continue to advance the Ii-KeySARS-CoV-2 peptide vaccine initiative. Now, as another pandemic threat is emerging with G4 SA
H1N1 swine influenza, we are in position to rapidly respond with our Ii-Key-H1 peptide vaccine
for which we have Phase I clinical safety and immunogenicity data. The Ii-Key-H1 peptide
vaccine uses an H1 epitope sequence that is 100% identical to the pandemic viruses 2009 H1N1
swine influenza and the 2004 H5N1 avian influenza, so the company is planning to evaluate the
sequence of the G4 EA H1N1 virus to determine if the Ii-Key-H1 vaccine program can be
reignited to rapidly respond to this new threat.”
NuGenerex Immuno-Oncology Announces
Plans to Address the New Emerging Pandemic Threat from
G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine
− NGIO has previously developed Ii-Key-H1 peptides for vaccines against epitopes to
2009 Swine Flu and 2004 Bird Flu with positive Phase I clinical safety and
immunologic data for Ii-Key-H1 peptide vaccine
− Ii-Key-H1 peptide sequence is 100% homologous in previous pandemic influenza
threats
− Potential to launch Ii-Key-H1 peptide vaccine for emerging pandemic threat from G4
EA H1N1 swine flu
− Published reference: Honglei et al. Prevalent Eurasian Avian-like H1N1 Swine
Influenza Virus with 2009 Pandemic Viral Genes Facilitating Human Infection.
Proceedings of the National Academy of Sciences; June 2020. (See Link)
https://www.pnas.org/content/early/2020/06/23...ticleShare
MIRAMAR, FL, July 2, 2020 – NuGenerex Immuno-Oncology today announced that the company
is launching a vaccine development effort to address the new, emerging pandemic threat from
a newly identified swine influenza virus. On June 29, 2020 scientists in China published a paper
in the Proceedings of the National Academy of Sciences identifying a new virus in pigs that has
the capacity to infect humans. This emerging virus is similar to the 2009 swine flu virus that is
estimated to have killed nearly 500,000 globally. Between April 12, 2009, and April 10, 2010,
the CDC estimates that the 2009 swine flu virus caused 60.8 million illnesses, 273,304
hospitalizations and 12,469 deaths in the United States. Of particular concern is that an
infection surveillance program with swine workers showed an elevated level of antibodies to
the G4 EA H1 influenza virus, indicating swine to human transmission and the potential for
another viral pandemic. NGIO is uniquely positioned to respond this pandemic threat as the
company has successfully completed a Phase I human clinical trial with an Ii-Key peptide
vaccine designed to elicit an immune response against the H1 hemagglutinin protein of the
2009 H1 swine influenza strain.
Joseph Moscato, CEO of NGIO stated, “Our Ii-Key immune activation technology is designed to
create targeted, highly specific vaccines that activate both the T-Cell and antibody responses
that make a “Complete Vaccine” against cancer antigens and viruses. The Ii-Key technology
platform was established to respond quickly, economically, and effectively to create vaccines
against viral and cancer antigens based upon the amino acid peptide sequences of the target
proteins that can be neutralized by an immune response. Importantly, Ii-Key peptide vaccines
have demonstrated safety, without signs of off-target immune responses or cytokine storm
effects in any of the Phase I and Phase II trials conducted to date. As such, the Ii-Key platform is
perfectly suited for inclusion in a pandemic preparedness portfolio, and we plan to pursue this
avenue to augment our clinical development program for Ii-Key immunotherapeutic cancer
vaccines as we progress toward a public listing for NuGenerex Immuno-Oncology on a national
exchange.”
Mr. Moscato continued, “With the explosion of the SARS-CoV-2 pandemic, we restarted the
pandemic vaccine development program conducted by NGIO from 2004 to 2010 and submitted
proposals to government agencies and international organizations to fund the development of
a COVID-19 vaccine. As we await the funding decisions, we continue to advance the Ii-KeySARS-CoV-2 peptide vaccine initiative. Now, as another pandemic threat is emerging with G4 SA
H1N1 swine influenza, we are in position to rapidly respond with our Ii-Key-H1 peptide vaccine
for which we have Phase I clinical safety and immunogenicity data. The Ii-Key-H1 peptide
vaccine uses an H1 epitope sequence that is 100% identical to the pandemic viruses 2009 H1N1
swine influenza and the 2004 H5N1 avian influenza, so the company is planning to evaluate the
sequence of the G4 EA H1N1 virus to determine if the Ii-Key-H1 vaccine program can be
reignited to rapidly respond to this new threat.”
